We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+8.32%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$520M
AUM Growth
+$42.5M
Cap. Flow
+$27.3M
Cap. Flow %
5.25%
Top 10 Hldgs %
74.31%
Holding
43
New
3
Increased
1
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$39.6M
2
ARTV
Artiva Biotherapeutics
ARTV
+$3.38M
3
JSPR icon
Jasper Therapeutics
JSPR
+$1.19M
4
BCAX
Bicara Therapeutics
BCAX
+$893K

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$6.66M
2
CLYM
Climb Bio
CLYM
+$4.61M
3
VRNA
Verona Pharma
VRNA
+$3.75M
4
IGMS
IGM Biosciences
IGMS
+$1.06M
5
JANX icon
Janux Therapeutics
JANX
+$980K

Sector Composition

Rank Sector Weight
1 Healthcare 98.79%
2 Financials 1.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRGX
1
DELISTED
CARGO Therapeutics
CRGX
$81.5M 15.66%
4,415,689
– –
MLYS icon
2
Mineralys Therapeutics
MLYS
$2.35B
$61.5M 11.81%
5,074,916
– –
SRRK icon
3
Scholar Rock
SRRK
$5.71B
$54.4M 10.45%
6,788,609
– –
NGNE icon
4
Neurogene
NGNE
$696M
$53.2M 10.22%
1,267,790
– –
ALMS
5
Alumis Inc
ALMS
$3.57B
$34.9M 6.71%
+3,266,498
New +$39.6M
ACLX
6
DELISTED
Arcellx
ACLX
$29.5M 5.68%
353,641
-100,000
-22% -$6.66M
LENZ
7
LENZ Therapeutics
LENZ
$172M
$28.7M 5.51%
1,208,473
– –
NKTX icon
8
Nkarta
NKTX
$162M
$17M 3.27%
3,768,035
– –
CLYM
9
Climb Bio
CLYM
$735M
$13.3M 2.55%
2,609,114
-652,279
-20% -$4.61M
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$12.7M 2.44%
967,527
– –
ZYME icon
11
Zymeworks
ZYME
$1.68B
$12.6M 2.41%
1,000,000
– –
SLRN
12
DELISTED
ACELYRIN
SLRN
$12.4M 2.39%
2,523,022
– –
CTNM
13
Contineum Therapeutics
CTNM
$526M
$11.3M 2.17%
588,816
-1
-0% -$19
JSPR icon
14
Jasper Therapeutics
JSPR
$22.9M
$11M 2.11%
584,642
+59,642
+11% +$1.19M
ABVX
15
Abivax
ABVX
$11B
$9.79M 1.88%
850,000
– –
RYTM icon
16
Rhythm Pharmaceuticals
RYTM
$7B
$9.04M 1.74%
172,647
– –
INZY
17
DELISTED
Inozyme Pharma
INZY
$8.17M 1.57%
1,562,500
– –
STRO icon
18
Sutro Biopharma
STRO
$379M
$7.6M 1.46%
219,681
– –
CYPH
19
Cypherpunk Technologies Inc
CYPH
$66.2M
$6.28M 1.21%
2,442,352
– –
GOSS icon
20
Gossamer Bio
GOSS
$66.5M
$6.05M 1.16%
6,130,268
– –
VRNA
21
DELISTED
Verona Pharma
VRNA
$5.62M 1.08%
195,225
-152,275
-44% -$3.75M
TNGX icon
22
Tango Therapeutics
TNGX
$4.34B
$4.85M 0.93%
630,000
– –
ARTV
23
Artiva Biotherapeutics
ARTV
$487M
$4.51M 0.87%
+291,666
New +$3.38M
SYRS
24
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.84M 0.74%
1,786,427
– –
IOBT
25
DELISTED
IO Biotech
IOBT
$3.82M 0.73%
3,640,015
– –
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q3 2024 Portfolio in Review

As of Q3 2024, Samsara BioCapital held 43 positions worth $520M, up 8.9% from $478M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Samsara BioCapital deployed $27.3M of net new capital in Q3 2024, opening 3 new positions and adding to 1 existing holding. Its largest new stake was Alumis Inc: 3,266,498 shares worth $34.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcellx, an estimated $6.66M trimmed.

  • Samsara BioCapital's largest Q3 2024 buy was Alumis Inc: 3,266,498 shares worth $34.9M.
  • Samsara BioCapital added most to Jasper Therapeutics in Q3 2024, an estimated $1.19M increase.
  • Samsara BioCapital's biggest Q3 2024 reduction was Arcellx, cutting an estimated $6.66M.
  • Samsara BioCapital fully exited IGM Biosciences in Q3 2024, selling an estimated $1.06M.
  • Samsara BioCapital's ten largest holdings make up 74% of its $520M portfolio in Q3 2024.
  • Samsara BioCapital opened 3 new positions and closed 1 in Q3 2024.
  • Samsara BioCapital's portfolio value rose 8.9% quarter-over-quarter to $520M.

Based on Samsara BioCapital's 13F filing for Q3 2024, filed 14 Nov 2024.